SIR4156 + semaglutide

SIR4156 + semaglutide is an investigational combination regimen being developed by Sironax for the treatment of obesity. The combination consists of SIR4156, a first-in-class, orally active allosteric activator of nicotinamide phosphoribosyltransferase (NAMPT), and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. NAMPT is a key rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), which is critical for cellular energy regulation, mitochondrial function, and tissue homeostasis. By combining NAMPT activation with GLP-1 receptor agonism, the regimen aims to promote weight loss while preserving lean muscle mass, reducing muscle atrophy, and improving physical performance. The combination is currently being evaluated in the Phase 2 FORGE-LM clinical trial in adults with obesity.

Other names

SIR-4156 + semaglutideSIR4156 and semaglutideSIR-4156 and semaglutideSIR 4156 and semaglutidesemaglutide + SIR-4156semaglutide + SIR4156